Omer Jamy1, George Yaghmour2, Felicia Hare3, Michael G Martin2. 1. Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, U.S.A. omerjamy@gmail.com. 2. Department of Hematology/Oncology, The West Clinic, University of Tennessee Health Science Center, Memphis, TN, U.S.A. 3. Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, U.S.A.
Abstract
BACKGROUND: Primary small cell carcinoma of the ovary (SCCO) is rare, making prognosis and outcomes largely undefined. PATIENTS AND METHODS: Using case listing session of SEER 18 (1973-2010), we examined outcomes for patients with SCCO. Analyses were conducted with SEER(*)Stat 8.1.2, Microsoft Excel 2007 and GraphPad Prism 6. Comparisons were made using the Chi-square test and log-rank test (Mantel-Cox) and all p-values were 2-sided. RESULTS: One hundred and eighty-one patients with SCCO with staging information were identified with a median age of 37 (range=10-91). Twenty-nine patients (15%) had localized, 19 (11%) regional and 133 (74%) distant disease at presentation. All patients with localized and 95% of patients with regional disease had surgery. The extent of surgery did not influence outcomes. Median overall survival (OS) varied by stage (67 months vs. 12 months vs. 9 months, p<0.001). Radiation was rarely used in localized (1 patient) or regional disease (3 patients). For comparison, 81,933 cases of SCLC were identified from the same database with a median age of 68; 8% of small cell lung cancer (SCLC) patients had localized, 29% regional and 63% distant disease. Outcomes were superior for patients with SCCO with localized disease (67 months vs. 16 months, p<0.001) but there was no clinically meaningful difference in patients with regional (12 months vs. 13 months, p=0.675) or distant disease (9 months vs. 7 months, p<0.001). CONCLUSION: SCCO presents at a younger age than SCLC but has a similar stage distribution. Patients with localized SCCO have a more favorable prognosis than patients with SCLC but patients with regional and distant disease have similar outcomes. Copyright
BACKGROUND:Primary small cell carcinoma of the ovary (SCCO) is rare, making prognosis and outcomes largely undefined. PATIENTS AND METHODS: Using case listing session of SEER 18 (1973-2010), we examined outcomes for patients with SCCO. Analyses were conducted with SEER(*)Stat 8.1.2, Microsoft Excel 2007 and GraphPad Prism 6. Comparisons were made using the Chi-square test and log-rank test (Mantel-Cox) and all p-values were 2-sided. RESULTS: One hundred and eighty-one patients with SCCO with staging information were identified with a median age of 37 (range=10-91). Twenty-nine patients (15%) had localized, 19 (11%) regional and 133 (74%) distant disease at presentation. All patients with localized and 95% of patients with regional disease had surgery. The extent of surgery did not influence outcomes. Median overall survival (OS) varied by stage (67 months vs. 12 months vs. 9 months, p<0.001). Radiation was rarely used in localized (1 patient) or regional disease (3 patients). For comparison, 81,933 cases of SCLC were identified from the same database with a median age of 68; 8% of small cell lung cancer (SCLC) patients had localized, 29% regional and 63% distant disease. Outcomes were superior for patients with SCCO with localized disease (67 months vs. 16 months, p<0.001) but there was no clinically meaningful difference in patients with regional (12 months vs. 13 months, p=0.675) or distant disease (9 months vs. 7 months, p<0.001). CONCLUSION: SCCO presents at a younger age than SCLC but has a similar stage distribution. Patients with localized SCCO have a more favorable prognosis than patients with SCLC but patients with regional and distant disease have similar outcomes. Copyright
Authors: Elizabeth K Lee; Katharine M Esselen; David L Kolin; Larissa J Lee; Ursula A Matulonis; Panagiotis A Konstantinopoulos Journal: JCO Precis Oncol Date: 2020-06-24
Authors: Leora Witkowski; Catherine Goudie; Pilar Ramos; Talia Boshari; Jean-Sebastien Brunet; Anthony N Karnezis; Michel Longy; James A Knost; Emmanouil Saloustros; W Glenn McCluggage; Colin J R Stewart; William P D Hendricks; Heather Cunliffe; David G Huntsman; Patricia Pautier; Douglas A Levine; Jeffrey M Trent; Andrew Berchuck; Martin Hasselblatt; William D Foulkes Journal: Gynecol Oncol Date: 2016-03-19 Impact factor: 5.482
Authors: George Yaghmour; Philippe Prouet; Eric Wiedower; Omer Hassan Jamy; Rebecca Feldman; Jason C Chandler; Manjari Pandey; Mike G Martin Journal: J Ovarian Res Date: 2016-08-26 Impact factor: 4.234